Centre Antoine Lacassagne, 36 voie Romaine, 06054 Nice Cedex, France Summary Recent biochemical and pharmacological findings concerning tamoxifen (TMX) have proven that both the unchanged drug and the main metabolites, N-desmethyltamoxifen (NDT) and 4-hydroxytamoxifen (4 OHT) are biologically active. An HPLC method based on on-line post-column UV irradiation with fluorescence detection is described. Optimized conditions allowed complete and rapid separation of TMX 40HT, NDT and two other recently reported metabolites, Y and Z. This method was applied to plasma and cytosol drug and metabolite analyses. In plasma, from the moment of initial drug administration until the steady state (after 1 month or more of continuous oral TMX treatment), the values of NDT to TMX ratios were completely reversed: 22 to 215 in mean %, P<0.01. The presence of metabolites Y and Z is significant. 40HT, hardly detectable at the first dose, was measured at the steady state with high interpatient variability. It is hypothesized that metabolite evolution with time may be due to auto-induction of drug metabolism. In cytosols, which were all obtained during continuous TMX treatment, the ratios between TMX and metabolites were comparable to those observed in plasma, but with greater interpatient variability. Metabolite Y was not detectable in cytosols. This variability was not linked to the levels of cytosolic oestradiol receptors before initiation of treatment.
Recent literature has provided new insights into the molecular pharmacology of tamoxifen (TMX) , its main metabolites, N-desmethyltamoxifen (NDT), 4-hydroxytamoxifen (40HT), and its more recently reported metabolites Y and Z (Kemp et al., 1983) . Although their biochemical identity has not yet been established, antioestrogen binding sites, which differ from oestradiol receptors (ER) , are the subject of current investigation (Sutherland & Murphy, 1980; Sudo et al., 1983; Ferno & Borg, 1985) . The binding affinity of E2, TMX, NDT, and 40HT relative to ER warrants increased study (Borgna & Rochefort, 1980; Fabian et al., 1981; Reddel et al., 1983; Miller et al., 1984) . These investigations have shown that 40HT, due to its preponderant affinity for ER, may play a critical role in the overall antioestrogenic action of the triphenylethylene derivatives. These studies have emphasized the need for an analytical method allowing simultaneous measurement of TMX and its main metabolites not only in plasma, but also in tumoral tissue in order to examine the possible relationship between distribution of TMX and/or metabolites and tumour response. Among recently developed methods, HPLC seems the most adequate since it is both sensitive, selective and suitable for routine analysis Camaggi et al., 1983 (Kontron, Zurich, Switzerland) was equipped with 10 and 15 nm slits; voltage was set at 600 V and the gain between 0.2 and 0.5. A Hewlett-Packard 3390A integrator (Arondale, PA, USA) was used for chromatographic recording. The UV on-line photocyclisation system was derived from a previously described system (Camaggi et al., 1983) : at the outlet of the column, a 6.5 m long Teflon capillary tube (0.35mm ID, 1.5mm OD) was arranged in 7 superposed circonvolutions (20cm diameter), with a Philips HPK 125 watt high pressure mercury lamp located in the centre. This irradiation system was enclosed in a wooden box with forced ventilation (20 x 30 x 40 cm). Columns The performance of a conventional stainless steel column (Zorbax CN 4.6 mm x 25 cm, Dupont Wilmington, DE, USA), flow rate 2.8 ml min-1, was compared to that of a radially compressed column (Rad Pak Cartridge CN 10 jm 100-8, Waters Associates, Milford, MA, USA), flow rate 2.5 ml min-1. Absorption and emission spectra were recorded for MTX, 4OHT, NDT, Y and Z (I jg ml -by stop-flow after on-line UV irradiation). Optimal routine conditions were: ex=258nm and em=378nm.
Sample preparation One ml blood samples were obtained in EDTA tubes. All glass tubes used for extraction were siliconated before use. The different types of plasma extractions described in the literature were compared:
Organic extraction Diethyl ether (Golander & Sternson, 1980) ; hexane-butanol 2% . Plasma (0.5 ml), spiked with 2 jg clomifene, was extracted twice with 4 vol of organic solvant each time. The organic phases were combined after centrifugation (2000rpm, 4°C, 10 min) and dried under N2 at 37°C. The dried residue was reconstituted in 250 jil of methanol, centrifuged (2000rpm, 4°C, 10min), and I0-I00,jl were injected.
Sep pak C18 extraction (Waters Associates, Milford, MA, USA) (Camaggi et al., 1983) One ml plasma, spiked with 4 jg clomifene, was treated with 2 ml water/methanol (1:1). After vortexing and centrifugation (2000rpm, 4°C, 10min), the supernatant was filtered through the SEP PAK cartridge previously activated by the passage of 3 ml of methanol followed by 3 ml of H20. Successive elutions were performed with 5ml H20, lml H20. CH3CN 1:1, and 0.5ml CH3CN. All eluates were discarded. The eluate from the last elution (5ml 0.3M phosphoric acid in CH3CN) was concentrated under vacuum (Buchi Rotavapor R). The dried residue was reconstituted with 250 pl of methanol and 50 pl were injected.
Results
Choice of the column system Figure 2 shows the HPLC profiles of TMX and its main metabolites separated by the conventional stainless steel column which gave the best performances. The values of the capacity factor K' were as follows: 4 OHT, 2.79; Z, 4.07; NDT, 4.93; TMX, 5.71; Y, 7.36; CMF, 7.50. reproducibility (spiked plasma at 100 ng ml1, 6 points) was respectively (coefficient of variation, %): 4 OHT, 10 and 11; Z, 7 and 11; NDT, 2 and 10; TMX, 3 and 14; Y, 3 and 7.
Plasma levels in treated patients Figure 3a gives the profile of a blank plasma and Figure 3b the plasma profile of a patient under TMX treatment.
Quantitatively, NDT appears the major metabolite; 40HT, Y and Z were formed to lesser degrees. Choice of the extraction process Recoveries were low (close to 30%) with cartridge extraction. Organic extraction was better: higher recuperation was obtained with 2% hexane-butanol, but the cleanest blank plasma resulted from diethyl ether extraction. This last extraction process was retained, and gave the following recoveries (spiked plasma at 100 ng ml-1): 4 OHT, 68%; Z, 62%; NDT, 92%; TMX, 67%; Y, 95%; CMF, 85%.
Linearity, sensitivity, reproducibility When the mean peak height (Y, mm) is considered as a function of spiked plasma extracted in triplicate by diethyl ether (x = 5, 10, 20, 50, 100 ng ml 1), regression lines (y = a + bx) were obtained with r2 at 0.99. The limit of sensitivity 2.5 times the baseline height for 500pi of diethyl ether extracted plasma (100 jl injected) was 2 ng ml1 (0.5 ng injected) for 40HT, Z and TMX, and 1.5ngml-1 (0.3ng injected) for NDT and Y. Intra-and inter-assay 
Discussion
The increasing clinical use of the antioestrogenic compound TMX has stimulated experimental efforts to elucidate its complex mechanism of action (cf. review of Furr & Jordan, 1984) . Sutherland and Murphy (1980) (Miller et al., 1984) whereas others do not (Raam et al., 1983; Ferno & Borg, 1985) . The relative affinity of E2, TMX, NDT, 4 OHT and Y for ER has been extensively explored, and general consensus is observed in the literature (Borgna & Rochefort, 1980; Fabian et al., 1981; Reddel et al., 1983; Miller et al., 1984; Tate et al., 1984) . Thus, 4 OHT appears to be equally or more potent than E2 for binding, whereas TMX, NDT and Y are bound with a lesser affinity. The observation that the drug concentration may condition the mode of action of triphenylethylene derivatives is an interesting acquisition (Reddel et al., 1985) . In brief, on a submicromolar level, TMX and its metabolites can inhibit cellular proliferation (Reddel et al., 1983; Briand & Lykkesfeldt, 1984; Taylor et al., 1984) ; for other cellular systems, TMX and its metabolites can stimulate cell proliferation (Reddel & Sutherland, 1984) . Above micromolar level, the antioestrogens are cytotoxic, the order of potency being NDT>40HT>TMX (Reddel et al., 1983) . All of these concepts require clinical confirmation and this necessitates a sensitive and specific method for analysis of TMX and related metabolites. In the present method, we adopted the principle of on-line post-HPLC Steroid receptors measured before initiation of treatment as previously described (Milano et al., 1983 column UV photocyclisation and fluorescence detection Camaggi et al., 1983) . The optimal analytical conditions described herein allowed complete separation and quantification of TMX from all of the metabolites that have been reported until now in humans (Furr & Jordan, 1984) . The resulting high sensitivity made possible a limit of detection in plasma in the range of 2 ng ml-1 for a small extracted volume (500 p1), thereby allowing acceptable blood sampling for repeated pharmacokinetic studies. In addition, cytosol measurements of TMX and metabolites were possible for breast cancer patients under treatment. Other workers, using a sophisticated gas chromatography mass spectrometry method, failed to detect 4OHT in cytosol (Daniel et al., 1981) . Application of the present method to blood monitoring and cytosol measurement of TMX and metabolites warrants several comments. (a) The relative proportions of NDT and TMX systematically reversed between the administration of the first drug dose and the pseudo-steady state (1 month or more of continuous oral treatment). This fact was reported previously (Fabian et al., 1980; Wilkinson et al., 1980; Kemp et al., 1983 ), but had not been quantified so accurately for individuai patients. This observation may be due to the longer elimination half-life of the metabolite . Enzymatic induction of N-demethylation is another possible explanation; this hypothesis is supported by the fact that continuous oral administration of the drug predisposes to a hepatic first pass effect. Supporting this view, 4 OHT, which was scarcely detectable at the first dose, was present at the steady state with high intersubject variability. Owing to the inherent difficulties in separating 40HT and NDT by classical thin layer chromatography, 4 OHT was not evaluable in previous pharmacokinetic studies (Wilkinson et al., 1980) . The presence of metabolite Z has also been previously signaled (Kemp et al., 1983) , but not quantified in a series of patients. Present data show that metabolite Z represents a significant part of the circulating drug profile. Experimental studies to evaluate its pharmacology and contribution to the activity of the parent drug appear justified, as has been done for metabolite Y .
(b) The distribution between the unchanged drug and its metabolites in cytosol is virtually the same as in plasma, although greater dispersion occurs in tumours. Metabolite Y was never detectable. Variability was not linked to the pretreatment ER content of the tumour cytosol. This observation confirms the need for more thorough investigations on the so-called antioestrogen binding sites and their possible role in drug-related actions. Although a correlation has recently been reported in animals between the tumour TMX content and tumoral regression (Daniel et al., 1984) , clinical extrapolation of the present results is beyond the scope of this paper.
